Investor Relations

High-growth company with focus on becoming a single-use pure player within all main endoscopy markets.

Latest news

07

Feb. 2023

Ambu Capital Markets Day 2023

Ambu invites institutional investors, analysts and financial media to the company’s Capital Markets Day on Tuesday 21 March 2023.

On 21 March 2023, Ambu will host its Capital Markets Day for institutional investors, analysts and financial media, from 10:00-16:00 CET, at the headquarters of Ambu A/S, Baltorpbakken 13, 2750 Ballerup, Denmark.

At the event, senior executives from Ambu and external speakers will join Chief Executive Officer, Britt Meelby Jensen, in sharing insights on the company’s new ZOOM IN strategy for delivering long-term sustainable double-digit revenue growth. This includes diving into the company’s strategic focus areas, its transformation program and providing a financial update on its long-term financial aspiration. Furthermore, the event will feature Q&A sessions as well as a product demonstration as the final item on the agenda.

All presentations and Q&As are held from 10:00-15:00 CET.

The product demonstration will run from 15:00-16:00 CET and will be for in-person attendees only.

The presentations will be held in English, and they will be recorded. After the event, the recorded presentations and the presentation materials will be published on Ambu’s website, Ambu.com/presentations/capital-markets-days.

SIGN UP FOR IN-PERSON ATTENDANCE

We encourage you to sign up for in-person attendance now. Please register your in-person attendance no later than Friday 3 March 2023.

Due to capacity constraints, please note that institutional investors, stock analysts and financial media are given in-person attendance priority to the event. Private investors are encouraged to follow the event online.

FOLLOW THE EVENT ONLINE

Ambu’s Capital Markets Day 2023 will be broadcasted live, and a video streaming link will be added to the Investor Relations site on the company’s website prior to the event.

Please note that online attendees will not be able to ask questions during the Q&A sessions. In addition, the product demonstration from 15:00-16:00 CET will not be livestreamed during the event. Instead, it will take place for in-person attendees only.

We look forward to seeing you at Ambu’s Capital Markets Day 2023.

Kind regards,

Ambu’s Investor Relations team

Download
Download the Ambu Capital Markets Day 2023 invite (pdf)

07

Feb. 2023

Interim report for Q1 2022/23 (no.4)

Ambu delivers solid performance for Q1 2022/23. The company posts 4% organic revenue growth for the quarter and continues to progress its new ZOOM IN strategy and global transform­ation program. Financial guidance maintained for the fiscal year 2022/23, with organic revenue growth at 5-8% and EBIT margin before special items at 3-5%.

Britt Meelby Jensen, Chief Executive Officer of Ambu, says:

In the first quarter of our fiscal year, we rolled out our ZOOM IN strategy across the organisation. The new strategy kicks off a transformation journey for Ambu, and we are progressing as planned with our transformation program, in support of our long-term financial aspirations. In a year of continued macro-economic uncertainty, I am pleased with the good momentum we have seen in many parts of our business. We posted strong revenue growth within urology and ENT, while our pulmonology business declined due to high comparables from Covid-19 last year, in line with expectations.

Across the business, our people are dedicated to supporting our customers and to making a difference for healthcare systems. With the challenges health systems currently face, such as staff shortages and constrained budgets, single-use solutions can help their situation, by improving workflow, increasing convenience and improving cost outcomes. I remain excited for the year – and for the meaningful opportunities that lie ahead of us as a company.”

 

FINANCIAL HIGHLIGHTS FOR THE QUARTER
Last year’s comparative figures are presented in brackets.​

  • Revenue for Q1 increased organically by 4% (-1%) to DKK 1,132m (DKK 1,031m). Reported growth for the quarter was 10% (2%).
  • Revenue in North America increased organically by 9% (18%), while revenue in Europe decreased by 4% (-16%). Rest of World posted organic growth of 14% (0%).
  • Endoscopy Solutions (formerly Visualization) revenue increased organically by 3% (-2%). In line with expectations, pulmonology declined 17%, due to high compa­rables from Covid-19 last year, while Endoscopy Solutions excluding pulmonology increased 47%, driven by strong growth in urology and ENT.
  • Anaesthesia sales increased by 4% (-6%), while Patient Monitoring (formerly Patient Monitoring & Diagnostics) posted organic growth of 6% (7%). Both business areas were impacted positively by the post-Covid-19 recovery, as well as a continued reduction of backlog orders.
  • Gross margin for the quarter was 58.5% (61.5%). The declining gross margin is driven by production costs, product mix and higher input costs.
  • EBIT before special items for the quarter was DKK 68m (DKK 40m), with an EBIT margin before special items of 6.0% (3.9%). This is driven by revenue growth and impacts from the cost reduction program initiated in Q4 2021/22, partly offset by inflationary effects and overheads from the Mexico ramp-up. The impact of foreign exchange rates on the EBIT margin was approximately 1 percentage point.
  • Free cash flow before acquisitions totalled DKK -174m (DKK -162m) for the quarter, including investments in innovation of DKK 51m (DKK 106m) and a reduction in payables of DKK 158m.
  • FY 2022/23 financial guidance stated on 15 November 2022 is maintained:
    • Organic revenue growth: 5-8%
    • EBIT margin before special items: 3-5%

OTHER BUSINESS-RELATED HIGHLIGHTS FOR Q1 AND THE PERIOD THEREAFTER

  • In November 2022, Ambu obtained European regulatory clearance (CE mark) of Ambu® aView™ 2 Advance, a high quality, portable HD monitoring and processing unit. The next-generation system offers compatibility with Ambu’s fifth-generation bronchoscope, as well as Ambu’s current and future single-use endoscopes across clinical specialties.
  • On 8 December 2022, Ambu announced that the company was one of the first medtech companies to achieve full compliance of all of its medical devices in line with the Medical Device Regulation (MDR) in Europe.
  • On 8 December 2022, a new French study* was published in the urology journal European Urology Focus, showing the environmental superiority of Ambu’s single-use cystoscope to reusable endoscopes. Concretely, the study established a difference of 33% in the climate change category, in favour of the Ambu® aScope™ 4 Cysto.
  • On 14 December 2022, at Ambu’s Annual General Meeting, two new members were elected to the Board of Directors. The new members are Shacey Petrovic, former President and CEO at Insulet Corporation, and Simon Hesse Hoffmann, professional investor and third generation in the family behind Ambu.
  • In January 2023, Ambu obtained FDA regulatory clearance of the Ambu® aScope™ 5 Broncho HD Sampler Set, a next-generation closed-loop sampling solution that improves the bronchoscopy fluid sampling workflow and reduces the risk of sample contamination.

*    Baboudjian, M., et al: “Life Cycle Assessment of Reusable and Disposable Cystoscopes: A Path to Greener Urological Procedures”, European Urology Focus, 8 December 2022

 

Q1 2022/23 CONFERENCE CALL

A conference call is scheduled for 7 February 2023, at 09:00-10:00 (CET). The conference is broadcast live via Ambu.com/webcastQ12023.

To ask questions in the Q&A session, please call one of the following numbers five minutes before the start of the conference and enter the following access code: 80974.

The presentation can be downloaded at ambu.com/presentations

Download
You can download this company announcement (pdf).

14

Dec. 2022

Decisions of Annual General Meeting 2022 (no. 3)

Today, 14 December 2022, Ambu A/S held its the Annual General Meeting of Ambu A/S, at which the following items were adopted.

The management’s report on the company's activities in the past year – Item 1
The shareholders noted the management’s report on the company’s activities in the past financial year.

Presentation for adoption of the annual report and consolidated financial statements – Item 2
The presented audited annual report for the financial year 2021/22 was adopted by the shareholders.

Presentation for adoption of the remuneration report – Item 3
The proposed and presented remuneration report for the financial year 2021/22 was adopted by the shareholders.

Proposal of the Board of Directors on the appropriation of profit in accordance with the adopted annual report – Item 4
The Ambu Group reported a net profit for the year of DKK 93 million.

Given the size of the net profit, the Board of Directors proposed that no dividend to be paid out. The proposal was adopted by the shareholders.

Approval of the Board of Directors' remuneration for the financial year 2022/23 – Item 5
The proposal of the Board of Directors that the annual general meeting resolved to approve the director’s remuneration for the financial year (2022/23) remains unchanged from the previous year and was adopted as follows:

  • Ordinary members of the Board of Directors receive basic remuneration amounting to DKK 350,000.
  • The Chairman receives three times the basic remuneration (DKK 1,050,000).
  • The Vice-chairman receives twice the basic remuneration (DKK 700,000).
  • In addition, each member of a Board committee receives remuneration of DKK 117,000 per com-mittee seat, however, the Chairman of a Board committee receives remuneration of DKK 175,000 per chairmanship.


Election of Chairman of the Board of Directors – Item 6
Jørgen Jensen was re-elected Chairman of the Board of Directors.

Election of Vice chairman of the Board of Directors – Item 7
Christian Sagild was re-elected Vice-chairman of the Board of Directors.

Election of other members of the Board of Directors – Item 8
Henrik Ehlers Wulff, Susanne Larsson and Michael del Prado were re-elected as members of the Board of Directors.

Shacey Petrovic and Simon Hesse Hoffmann were elected as new members of the Board of Directors.

Election of auditor – Item 9
EY Godkendt Revisionspartnerselskab was re-elected as the company’s auditor.

Proposals from the Board of Directors – Item 10.1
The Board of Directors proposed that in accordance with section 198 of the Danish Companies Act the general meeting authorizes the Board of Directors in the period up to and including 13 December 2027 and in one or more stages to acquire treasury shares for a nominal value of up to DKK 12,885,821 corresponding to 10 % of the company’s share capital, provided that the purchase price does not deviate by more than 10 % from the most recently quoted market price for the company’s B-shares at the time of the acquisition. The proposal was adopted by the shareholders.

Authorization to the Chairman of the meeting – Item 11 
The Chairman of the meeting was, with full right of substitution, authorized to apply for registration of the resolutions passed and to make any such amendments thereto as the Danish Business Authority or other authorities may require or request as a condition for registration or approval, as well as to continuously make and apply for registration of linguistic and other non-substantive adjustments to the company’s Articles of Association.
 

You can read the full company announcement here.

Financial Reports

Get the latest annual & quarterly reports
Read more

Annual Key Figures

Get an overview of Ambu's key figures
Read more

Presentations

Get the latest investor presentations and webcasts
Read more

Upcoming events

21

Mar. 2023

Capital Markets Day

Ambu invites institutional investors, analysts and financial media to the company’s Capital Markets Day on Tuesday 21 March 2023.


On 21 March 2023, Ambu will host its Capital Markets Day for institutional investors, analysts and financial media, from 10:00-16:00 CET, at the headquarters of Ambu A/S, Baltorpbakken 13, 2750 Ballerup, Denmark.

At the event, senior executives from Ambu and external speakers will join Chief Executive Officer, Britt Meelby Jensen, in sharing insights on the company’s new ZOOM IN strategy for delivering long-term sustainable double-digit revenue growth. This includes diving into the company’s strategic focus areas, its transformation program and providing a financial update on its long-term financial aspiration. Furthermore, the event will feature Q&A sessions as well as a product demonstration as the final item on the agenda.

All presentations and Q&As are held from 10:00-15:00 CET.
The product demonstration will run from 15:00-16:00 CET and will be for in-person attendees only.

The presentations will be held in English, and they will be recorded. After the event, the recorded presentations and the presentation materials will be published on Ambu’s website, Ambu.com/presentations/capital-markets-days.


SIGN UP FOR IN-PERSON ATTENDANCE

We encourage you to sign up for in-person attendance now. Please register your in-person attendance no later than Friday 3 March 2023.

Due to capacity constraints, please note that institutional investors, stock analysts and financial media are given in-person attendance priority to the event. Private investors are encouraged to follow the event online.
 

FOLLOW THE EVENT ONLINE

Ambu’s Capital Markets Day 2023 will be broadcasted live, and a video streaming link will be added to the Investor Relations site on the company’s website prior to the event.

Please note that online attendees will not be able to ask questions during the Q&A sessions. In addition, the product demonstration from 15:00-16:00 CET will not be livestreamed during the event. Instead, it will take place for in-person attendees only.

 

We look forward to seeing you at Ambu’s Capital Markets Day 2023.

Kind regards,

Ambu’s Investor Relations team

03

May. 2023

Earnings release Q2 2022/23

31

Aug. 2023

Earnings release Q3 2022/23

News from Ambu

Sign up and receive financial news and company announcements from Ambu

Sign up

 

keyboard_arrow_up